nejm semaglutide ckd Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT trial significant 24% reduction in kidney

Prioritize protein at every meal and snack to prevent muscle loss during rapid weight reduction

Pricing Comparison: TomorrowsRx vs Traditional Care and Cost Reality Understanding the cost context can help you evaluate whether TomorrowsRx represents good value relative to other pathways for accessing GLP-1 medications

Pharmacy in Focus Navigating the GLP-1 conundrum: Demand, cost, and sustainability Expanding drug indications are driving historic change Todays health landscape is changing fast

Dual agonists like tirzepatide target both GLP-1 and GIP receptors, making them distinct from medications that target GLP-1 alone

We provide evidence that this targeting concept can be used to antagonize NMDA receptors specifically in GLP-1-receptor-positive neurons to reverse obesity and correct symptoms of cardiometabolic diseases in preclinical obesity models